Abstract Objective: Primary objective was to verify whether breast cancer patients aged less than 40 years at diagnosis have poorer prognosis than older patients. Secondary to assess prognostic factors influencing disease free survival. Methods: 941 women were diagnosed with non-metastatic breast cancer at NCI, Cairo in 2003. Epidemiologic, clinico-pathological characteristics, treatment modalities and disease free survival were compared among the two age groups. Prognostic factors were evaluated for association with disease-free survival. Results: One hundred-eighty-one patients (19.2%) were younger than 40 years and 760 (80.8%) were older. Older women presented with higher rates of comorbidities and younger women presented with more hormone non-responsive tumors. Young women presented with larger tumors pT4 = 13.8% compared to 8.6% in older women, yet not significant. Young women were treated with more conservative surgery, more adjuvant chemotherapy and radiotherapy while older women with more radical mastectomies and more hormonal treatment. Recurrence rates were significantly higher among young women 44.2% compared to 34.5% in older women. Five year disease free * Corresponding author. Tel.: +20 2 2364 1772. E-mail address: nelly26660@gmail.com (N.H. Alieldin). Peer review under responsibility of The National Cancer Institute, Cairo University.
Introduction
Among women in Egypt, breast cancer is a challenging health problem coming on top of all malignancies [1] with a poor outcome compared to international figures [2] . Many studies showed that age at diagnosis of breast cancer in Arab countries is a decade younger than that in Western countries [3] [4] [5] . In the US median age at presentation for breast cancer is 61 years [5] , compared to 50-54 years in Egypt [1] . A 10-year survey of breast cancer treatment at the United States showed that 6.4-7.8% of women are diagnosed younger than 40 years of age [6] . Several studies investigating breast cancer in young women have shown that it is more aggressive, with higher mortality and recurrence rates compared with older women [3, [7] [8] [9] . Chung and colleagues [8] have found that women who were diagnosed with invasive breast cancer at 40 years of age and younger had a poor 5 year disease free survival of 60.8% second only to women older than 80 years of age. Though a population-based study in Switzerland showed that young women presented with larger tumors and more aggressive tumors, it found no effect of age on survival [10] . Results of a study in 1992 in Saudi Arabia and another study in 2004 in Singapore did not report an adverse effect of age on survival [11, 12] . A recent study in Japan aimed at identifying the prognostic value of age in premenopausal women younger than 40 years of age, found that age at diagnosis was not an independent prognostic factor on survival [13] . Although the negative prognostic impact of young age has been substantiated in numerous studies, the mystery of young age at diagnosis has not been resolved in Egypt. The primary aim of the present study is to verify whether breast cancer patients aged less than 40 years old at diagnosis have poorer prognoses than those aged 40 years or more. The secondary objective is to assess prognostic factors influencing disease free survival in patients with breast cancer.
Patients and methods

Patients and treatment
From the database of cancer registry system at National Cancer Institute Hospital, Cairo, Egypt, women who were diagnosed with primary breast cancer in the period between January and December 2003 with stage I-III disease were included. The medical records of the patients included in the study were reviewed. Information derived from the database and medical records included epidemiologic, clinical and histological variables. Epidemiologic variables included age; residence, and marital status. Age was dichotomized (younger than 40 years and 40 years of age and older). Women younger than 40 years of age were grouped together, as they represent a special high-risk population. Clinicopathologic data included menopausal status, family history of breast cancer; history of diabetes mellitus, hypertension, laterality of the lesion, pathologic types, pathologic grade, T stage (primary tumor), N stage (regional lymph node); estrogen receptor (ER) and progesterone receptor (PR) status; operative procedures; radiation therapy; adjuvant systemic therapy (chemotherapy and hormonal therapy).
In all cases, T and N stages were assessed according to the UICC TNM classification (6 th edition). ER and PR expression were determined as positive or negative by enzyme immunoassay or immunohistochemistry (IHC).
Regular schedule of patients' follow up at NCI, Cairo is every 3-6 months during the first 5 years and every 6-12 months from the 5 th to 10 th year. Physical examination, mammography with or without breast ultrasound, chest Xray, abdominal ultrasonography and bone scintigraphy are performed when the patients complain of any symptoms and/or tumor recurrence is suspected. Approval of Institutional Review Board was achieved for the current study.
Statistical methods
Chi-square test was used to assess differences in clinical and pathological factors between the two age groups of patients. A p value 60.05 was considered statistically significant. Disease-free survival (DFS) was defined as the time from surgical resection to the date of any of the following events: locoregional relapse, distant relapse, or death. Locoregional relapse was defined as the reappearance of cancer in the ipsilateral breast, chest wall or regional lymph nodes. Distant relapse included metastasis in nonvisceral sites (soft-tissue and/or bone) or visceral (including lung, liver, brain and other organs). DFS time was estimated by the Kaplan-Meier method and compared among patient subsets using the log-rank test. In univariate analyses, the following prognostic factors were evaluated for their potential associations with DFS: age at the time of diagnosis, family history of breast cancer, hypertension and diabetes (as commonest co-morbidities), pT stage, pN stage, histological type, histological grade, ER and PR receptor status, operative procedure, administration of adjuvant systemic therapy and radiation therapy. Multivariate analysis of potential prognostic factors was performed to generate a Cox proportional hazards model. Multivariate models were created using age at diagnosis and other variables that either showed significant or borderline association or believed to confound the effect of other prognostic variables on DFS. All tests were two-tailed, with p value set significant at 0.05 level. The statistical software SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses. 
Results
Patient characteristics
Out of a total of 1128 women diagnosed with primary breast cancer at the NCI, Cairo, Egypt in 2003, patient with stage IV, metastatic at presentation, comprised 16.6% of all women and 941 patients were stage I-III. Of which 181 (19.2%) were less than 40 years at diagnosis (young women), and 760 (80.8%) were 40 years or more (older women) (Table 1). The median age at diagnosis was 49.1 years (range 23-90 years). Analyses illustrated significant differences between age groups in several patient and tumor characteristics. Older women were more hypertensive and diabetic. The biologic characteristics of the tumors in younger women were also significantly different from tumor characteristics in older women. Compared with older women, younger women were more likely to have negative estrogen receptors, and negative progesterone receptors (p value 0.006, and 0.04). Finally, treatment differed between younger and older women, with younger women receiving more conservative mastectomies (20.4% versus 15.3%) and less modified radical mastectomies (MRM) (66.3% versus 71.8%) than their older female counterparts, yet not significant. On the other hand strategy in young women is toward adjuvant chemotherapy and adjuvant radiotherapy (77.9% versus 64.1% and 68.5% versus 58%, respectively) as compared to older women. Hormonal treatment in the young group was significantly lower than the old group. Although young women presented with larger tumor size pT4 = 13.8% compared to 8.6% in older women, the absolute difference was small and not significant. Patient, tumor, and treatment characteristics of the two groups are summarized in Table 1 .
During a median follow-up of 23 months (range 1-128 months), 342 patients (36.3%) experienced recurrence events (distant relapse 33.5% and locoregional relapse 6.6%). Recurrence events mainly distant relapses were significantly higher among young women than older women. The 3, 5 and 10-year disease free survival in the whole study group was 60.1 ± 2.0%, 46.4 ± 2.2% and 35.1 ± 2.5%.
Univariate analyses
For breast cancer patients treated at NCI, Cairo, univariate analyses showed that significant adverse factors associated with DFS included higher T stage (pT2-4), positive lymph nodes (pN1-3), grade II + III, negative ER status, absence of adjuvant systemic therapy and receiving adjuvant radiotherapy. Age was not found to impact significantly DFS despite the fact that 5 year DFS in older women was 10% higher than younger women and hazard of relapse in young women is 23% higher than old women (crude hazard ratio 1.23 (0.96-1.58)) ( Table 2 and Figs. 1-4) .
Multivariate analyses
In the present study for all ages, multivariate analyses identified positive axillary lymph nodes (pN2-pN3), larger tumor size (pT3-pT4), hypertension, tumor histopathology (lobular carcinomas) and lack of adjuvant systemic treatment as independent factors associated with poor DFS (Table 2) . Age, represented as either a categorical or a continuous variable, was not an independent prognostic factor in multivariate analyses. The negative impact of prognostic factors on DFS is as follows: hypertension (hazard ratio HR [15] . This disparity is attributed to differences in population structure with more young population in Egypt and Saudi Arabia. The distinction between young and 'very young' premenopausal patients is unclear but most investigators who chose to dichotomize their analysis used an age limit of 35-40 years [16] . With different age limits many studies reported young age as an independent adverse prognostic factor in breast cancer with more aggressive presentation, high mortality and high recurrence rates [7] [8] [9] , while others were not in agreement that young onset breast cancer is associated with poor prognosis [10] [11] [12] . Women younger than 40 years in the current study showed a slight (22%), but non-significant increase in the hazard of relapse compared to older women, (adjusted 19) . In spite of the aggressive treatment received by our young age group (more adjuvant chemotherapy and radiotherapy), relapse rates either systemic or loco-regional were significantly higher in young than old women. In the present study and after 10 years of diagnosis, relapse rate was 44.2% in young women compared to 34.5% in older women. The higher rate of relapse in the young group could be explained by larger tumor size at presentation and more negative hormone receptors. Also it could be explained by more conservative surgical treatment and less adjuvant hormonal treatment in young women. Elkum et al. [14] using 40 years and younger as an age limit reported a significant increase in the risk of relapse by 51% (HR = 1.51, 95% CI (1.03-2.23), p value = 0.035) among young women. Anders et al. [17] reported worse prognosis when breast cancer diagnosis is before age of 40 years accounting for patient, pathologic and treatment characteristics (RR = 1.6, P = 0.009).
In a Japanese study [13] comparing disease free survival in women younger than 35 years and those 35-39 years, after a median follow-up of 80 months (range 5-186) months, 35.5% of all patients experienced DFS events. The discrepancy in relapse rate between Egyptian and Japanese women younger than 40 years is supported by the low 5 year DFS in the Egyptian patients (38.9%) compared to 70-73% among Japanese women [13] . Also 5-year DFS among Saudi women 40 years and younger was higher than our study (77.4%) [14] . The exceptionally high rate of relapses in Egyptian patients regardless of age is related to more positive node status (median of pN2) at presentation compared to median of pN0 in Japanese women [13] and a median of pN1 in Saudi women [14] . Although the Japanese study did not confirm the adverse role of age in premenopausals, the unpublished data confirm that breast cancer patients aged less than 40 years have poorer DFS than those aged 41-49 years (5-year DFS: 79 vs. 86%, p = 0.04) [13] . In spite of the low estimate of 5 year DFS (46.4%) in the present study for the whole study group, it was superior to a study conducted at National Cancer Institute of Mexico which shows a lower estimate for 5 year DFS (less than 20%) [18] . Advanced tumor size and more than 85% positive nodes at presentation in NCI, Mexico explained this poor figure.
Also an MD dissertation (unpublished) carried out at NCI, Cairo, 2006 , that compared DFS in 3 study periods (1990, 1995 and 2000) in women with operable breast cancer showed that 5 year DFS across the 3 periods was 22%, 48%, and 45%. The 5 year DFS for young women (635 years) in this study was 32% compared to 40% in older women, HR = 1.24 and p = 0.13. At NCI, Cairo, effect of age on prognosis did not seem to be changed as compared to the present study and the apparent improvement in survival may not mirror improvement or change in treatment strategy but rather stage migration.
In agreement with the present study van de Vijver et al. [19] revealed that age was not an independent prognostic factor, while gene-expression profile was a significant predictor of disease outcome in younger women with breast cancer. Several studies supported the conclusion that age itself had no influence on the prognosis but association of poor prognosis with young age at diagnosis is explained by higher proportion of aggressive tumors in younger women in terms of higher T stage, positive lymph nodes, endocrine non-responsiveness, high grade and high proliferating fraction [7, 9, [20] [21] .
Secondary objective in this study is to find other prognostic factors associated with poor prognosis. Though young age was not found to be an adverse independent prognostic factor for DFS, being hypertensive, with large tumor size, positive nodal status, invasive lobular carcinoma, and receiving no adjuvant systemic treatment was adversely and independently associated with disease free survival. Negative ER hormonal receptor status showed a tendency to adversely affect DFS (adjusted HR = 1.45 (0.93-2.26), p = 0.09). In univariate analysis only, patients who were treated with radiotherapy and radical surgery had significantly worse DFS. These findings reflect the significantly higher proportion of positive axillary lymph nodes and advanced stage in those patients. Axillary positive nodes in women with primary breast cancer and in many studies represent an independent poor prognostic parameter across all age strata. This finding is supported in the present study (data not shown).
In support to our findings, recent studies showed that the presence of comorbidities as hypertension and type II diabetes could increase the risk of recurrence and mortality among women with breast cancer [22] [23] . A study conducted on 2389 women with stage I and II invasive breast cancer who were diagnosed and treated at the M.D. Anderson Cancer Center between 1985 and 2000 found hypertension (HR 1.22; 95% CI 0.99-1.49) to be statistically significant and a potential prognostic factor for disease-free survival and overall survival. The study suggests that co-morbid conditions like hypertension could account for the racial disparities that exist when comparing breast cancer survival rates. However future studies should investigate this relationship further [22] .
Previous studies have identified axillary lymph node status, hormone receptors and HER2 status, tumor size, histological grade, operative procedure, radiation therapy, adjuvant systemic therapy, and age, 35 years or 40 years as independent prognostic factors in patients with breast cancer [9] [10] 14, 24, 25] .
In conclusion, our results did not show a significant adverse effect on DFS for young age at diagnosis. However, the independent factors associated with poor DFS included hypertension, positive axillary lymph nodes (pN2-pN3), tumor size (pT3-pT4), lobular carcinoma type and lack of adjuvant systemic therapy. Non responsive hormone receptors differ considerably between the two age groups. An important finding is the advanced stage at presentation for all ages, and the exceptionally high recurrence rate for the young age group. Preventive and treatment strategies for breast cancer in Egypt should be extensively revised with tremendous concern for nationwide screening programs for breast cancer.
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